Transaction DateRecipientSharesTypePriceValue
17th December 2020Edward Wholihan68,550Open or private sale$1.36$93,228.00
17th December 2020Edward Wholihan164,822Exercise of derivative$0.00
17th December 2020Louis Md Brenner103,116Open or private sale$1.36$140,237.76
17th December 2020Louis Md Brenner247,932Exercise of derivative$0.00
Allena Pharmaceuticals
Allena Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Allena Pharmaceuticals, Inc. engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes Reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011.

Ticker: ALNA
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1624658
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags